Navigation Links
InterMune Reports Fourth Quarter and Full Year 2008 Financial Results and Business Highlights
Date:2/26/2009

p>
    Recent Highlights
    Pirfenidone:

    -- On October 16, 2008 Shionogi & Co., Ltd of Japan, which has rights to
       pirfenidone in Japan, reported approval of its j-NDA to market
       pirfenidone as Pirespa(R) in IPF.
    -- On February 3, 2009, InterMune reported results from its Phase 3
       CAPACITY program for pirfenidone in IPF, which consisted of two,
       multinational, randomized, double-blind, placebo-controlled clinical
       trials named CAPACITY 1 and CAPACITY 2.
        - The primary endpoint of change in percent predicted Forced Vital
          Capacity (FVC) at Week 72 was met with statistical significance in
          CAPACITY 2 (p=0.001), as were the secondary endpoints of categorical
          change in FVC (p=0.001) and Progression-Free Survival  (p=0.023).
        - The primary endpoint was not met in CAPACITY 1 (p=0.501), but
          supportive evidence of a pirfenidone treatment effect was observed
          on a number of measures and at various time points.  In CAPACITY 1,
          there was evidence of a pirfenidone treatment effect on the
          pre-specified secondary endpoint of Six-Minute Walk Test distance
          (p = 0.001) when compared to placebo.
        - Pirfenidone was safe and generally well tolerated in both CAPACITY
          studies.  There was no difference between pirfenidone and placebo in
          the percentage of patients that experienced a serious adverse event
          (SAE) and the pattern of adverse events (AEs) was, in general,
          comparable to that observed in previous clinical studies of
          pirfenidone.
        - InterMune is preparing an NDA for submission to the FDA, to be
          followed by an MAA submission to the European Medicines Agency
          (EMEA).
    -- InterMune reported that 603 patients from CAPACITY have been enrolled
       in RECAP, the on-going open-label roll-over study from CAPACITY to
       evaluat
'/>"/>
SOURCE InterMune, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. InterMune to Release Fourth Quarter, Full Year 2008 Financial Results on February 26
2. InterMune Announces Issuance of U.S. Patent for ITMN-191
3. InterMune Announces Pricing of Public Offering of 3,500,000 Shares of Common Stock
4. InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF
5. InterMune to Present at J.P. Morgan Healthcare Conference
6. InterMune to Present at Deutsche Bank Biotech Boston Confab
7. InterMune Reports Third Quarter 2008 Financial Results and Business Highlights
8. InterMune to Release Third Quarter 2008 Financial Results on November 6
9. InterMune Reports Japanese Regulatory Approval of Pirfenidone in IPF
10. InterMune to Present Four Abstracts on HCV Protease Inhibitor ITMN-191 at the AASLD Meeting
11. InterMune Earns Development Milestone in HCV Protease Inhibitor Collaboration With Roche
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/12/2014)... -- Research and Markets has announced the ... Report 2014" report to their offering. ... is a professional and in-depth study on the current ... The report provides a basic overview of ... structure. The dry film photoresist market analysis is provided ...
(Date:9/11/2014)... (PRWEB) September 12, 2014 RURO, ... radio-frequency identification (RFID) solutions and sample management solutions ... , RURO completed work on the most recent ... and it has already seen mass adoption, especially ... release of version 5.0 brought an entirely new ...
(Date:9/11/2014)... thick sheet of carbon, can be randomly decorated with ... that could have a significant impact on the chemical, ... provide an ultra-strong, non-corrosive coating for a wide range ... be used to paint various surfaces ranging from glass ... chemical treatment, the resulting coatings behave like graphite in ...
(Date:9/11/2014)... 2014 The Registration Committee today ... now open for Pittcon 2015, the world’s largest ... event will be held March 8-12, 2015, at ... , The discounted registration fee of $175 ... 2/20/2015). This affordable price includes unlimited week-long access ...
Breaking Biology Technology:Global Dry Film Photoresist Industry Report 2014 2Limfinity® Version 5.1 Available 2Graphene paints a corrosion-free future 2Conferee Registration Opens for Pittcon 2015; Housing & Travel Open for Reservations 2
... Feb. 28, 2011 Idenix Pharmaceuticals, Inc. (Nasdaq: ... discovery and development of drugs for the treatment of ... the fourth quarter and year ended December 31, 2010. ... totaled $46.1 million. Business HighlightsIDX184 ...
... SAN DIEGO, Feb. 28, 2011 Verenium Corporation (Nasdaq: ... of high-performance specialty enzymes, today announced that Terminal 6, ... has successfully begun use of Verenium,s Purifine enzymatic degumming ... Argentina. Purifine enzymatic degumming is a novel process that ...
... (CTI) (Nasdaq and MTA: CTIC) announced today that it ... Conference on Thursday, March 3rd at 10:25 AM Pacific ... Center, Seattle, Washington. WBBA Life Science Innovation Northwest ConferenceCTI ... PM CETRoom 607, Washington State Conference CenterMedia Contact:Dan Eramian ...
Cached Biology Technology:Idenix Pharmaceuticals Reports Fourth Quarter and Year End 2010 Financial Results 2Idenix Pharmaceuticals Reports Fourth Quarter and Year End 2010 Financial Results 3Idenix Pharmaceuticals Reports Fourth Quarter and Year End 2010 Financial Results 4Idenix Pharmaceuticals Reports Fourth Quarter and Year End 2010 Financial Results 5Idenix Pharmaceuticals Reports Fourth Quarter and Year End 2010 Financial Results 6Idenix Pharmaceuticals Reports Fourth Quarter and Year End 2010 Financial Results 7World's Largest Soybean Processing Industrial Complex Converts Half of Capacity to Usage of Verenium's Purifine® PLC Enzymatic Degumming Process Engineered and Installed by Alfa Laval 2World's Largest Soybean Processing Industrial Complex Converts Half of Capacity to Usage of Verenium's Purifine® PLC Enzymatic Degumming Process Engineered and Installed by Alfa Laval 3World's Largest Soybean Processing Industrial Complex Converts Half of Capacity to Usage of Verenium's Purifine® PLC Enzymatic Degumming Process Engineered and Installed by Alfa Laval 4
(Date:9/12/2014)... extraction of type I collagen fibrils, in vitro as ... circular cross sections stay distributed in a range going ... of them. Jean Charvolin and Jean-Francois Sadoc from the ... therefore that, once the growth of the fibrils has ... be limited by internal physical stresses generated during the ...
(Date:9/12/2014)... strange thing happened on the way to dealing ... trillions of dollars, worth of previously unreachable oil ... environmental costs and benefits from "fracking," ... and chemicals deep into underground rock formations, are ... academic studies and government databases. The survey covers ...
(Date:9/12/2014)... Washington , September 12, 2014 ... source covering leading sectors including biometrics and mobile tech, issues ... launch of Apple Pay, its new payment service. ... founder of the Secure Identity and Biometrics Association (SIBA) and ... NXTD ) a company that is introducing its own ...
Breaking Biology News(10 mins):Conjecture on the lateral growth of Type I collagen fibrils 2Stanford-led study assesses the environmental costs and benefits of fracking 2Stanford-led study assesses the environmental costs and benefits of fracking 3Stanford-led study assesses the environmental costs and benefits of fracking 4Biometric Experts Comment on Launch of Apple Pay Smart Wallet Payment Service 2Biometric Experts Comment on Launch of Apple Pay Smart Wallet Payment Service 3Biometric Experts Comment on Launch of Apple Pay Smart Wallet Payment Service 4Biometric Experts Comment on Launch of Apple Pay Smart Wallet Payment Service 5
... the largest scientific conference devoted primarily to osteoporosis, will ... session focused on four key topics in nutrition and ... the MRC Epidemiology Resource Centre at the University of ... the University of Oxford, will speak on the developmental ...
... improve forecasts of dust storms in the American Southwest ... announced the finding as a five-year NASA-funded project nears ... of the University of New Mexico in Albuquerque, and ... scientists evaluated the influence of space-based observations on predictions ...
... year, some 29,000 adults and 2,000 children are diagnosed with ... abnormal production of white blood cells in the bone marrow. ... also destroys normal cells. But what if a way could ... A team of Syracuse University researchers believes it may have ...
Cached Biology News:Nutrition and bone health session to open the IOF World Congress on Osteoporosis in Bangkok 2NASA-enhanced dust storm predictions to aid health community 2NASA-enhanced dust storm predictions to aid health community 3Syracuse University researchers discover new way to attack some forms of leukemia 2Syracuse University researchers discover new way to attack some forms of leukemia 3
... to Salmonella typhimurium The genus Salmonella is ... is composed of Gram-negative bacilli that are facultative ... the "H" or flagellar antigen (phase 1 & ... the LPS moiety) and the "Vi" or capsular ...
... 50 mg/L streptomycin sulfate, 100 mg/L kanamycin ... magnesium chloride. The use of a balanced ... generally attributed to early workers in the ... solution of inorganic salts designed to maintain ...
... The micro 1 is a dramatic breakthrough ... from 1mL with 10nL resolution, the micro 1 ... benchtop dispenser. And, the micro 1 never needs ... , Touch Screen programming on an LCD Display ...
... ( Abpromise for all tested ... Synthetic peptide: VEEESFGPQPISRLE conjugated to KLH, ... 15-29 of Human Rad51 ... Swiss Protein ID: ...
Biology Products: